论文部分内容阅读
目的比较依那普利与厄贝沙坦治疗老年慢性心力衰竭(CHF)患者的临床疗效。方法 81例老年慢性心力衰竭患者,随机分为对照组、依那普利组和厄贝沙坦组,各27例。观察三组疗效和不良反应。结果依那普利组和厄贝沙坦组左心室舒张末期容积(LEDV)、左心室收缩末期容积(LESV)、射血分数(EF)及总有效率与对照组比较,差异均有统计学意义(P<0.05);厄贝沙坦组胃肠道反应2例,头痛3例,头晕3例,服用数天后症状逐渐消失;依那普利组干咳8例,有5例于第4周退出试验。结论依那普利与厄贝沙坦均可改善慢性心力衰竭患者的心功能,但厄贝沙坦耐受性好,不良反应少,更适合老年患者应用。
Objective To compare the clinical efficacy of enalapril and irbesartan in the treatment of elderly patients with chronic heart failure (CHF). Methods A total of 81 elderly patients with chronic heart failure were randomly divided into control group, enalapril group and irbesartan group, with 27 cases in each group. Three groups were observed efficacy and adverse reactions. Results The changes of left ventricular end-diastolic volume (LVEV), left ventricular end-systolic volume (LESV), ejection fraction (EF) and total effective rate in enalapril and irbesartan groups were statistically different from those in control group (P <0.05); 2 cases of irbesartan group gastrointestinal reactions, headache in 3 cases, dizziness in 3 cases, after taking a few days the symptoms gradually disappear; enalapril group of dry cough in 8 cases, 5 cases in the first 4 weeks Exit the test. Conclusion Both enalapril and irbesartan can improve cardiac function in patients with chronic heart failure. However, irbesartan is well tolerated and has few adverse reactions, which is more suitable for elderly patients.